What is claimed is:

1. A compound of formula (1) or formula (2)



(1)



(2)

wherein:

X and Y independently are N or CH wherein at least one of X and Y is N;

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, thio$(C_1\text{-}C_4)$alkyl, $NO_2$, NH$(C_1\text{-}C_4)$alkyl and N$((C_1\text{-}C_4)\text{alkyl})_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, or

5 or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, thio$(C_1\text{-}C_4)$alkyl, NH$(C_1\text{-}C_4)$alkyl, N$((C_1\text{-}C_4)\text{alkyl})_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N,

Z is H, 4-aminophenyl, $SO_2R_3$ or $COR_3$ wherein $R_3$ is $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, Ar as defined above, $(C_2\text{-}C_6)$alkenyl or $(C_2\text{-}C_6)$alkynyl;

$R_1$ is H, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl or Ar as defined above;

R' is H or $(C_1\text{-}C_4)$alkyl; and

when Z is H, $R_2$ is a selected from the group consisting of:

cyano,

$C(O)$-$OR_{a_1}$ wherein $R_{a_1}$ is methyl, ethyl or isopropyl,

$C(O)$-$NHR_{a_2}$ wherein $R_{a_2}$ is cyclopropyl,

$C(O)$-$N(R_{a_2}')$, wherein $N(R_{a_2}')$ is aziridinyl or azetidinyl, optionally substituted with $(C_1$-$C_4)$alkyl or Ar as defined above,

$C(O)$-$N(R_{a_3})$-$OR_{a_3}$ wherein each $R_{a_3}$ may be identical or different and each $R_{a_3}$ is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

$C(O)R_{a_4}$ wherein $R_{a_4}$ is Ar as defined above or $(C_3$-$C_5)$cycloalkyl optionally substituted with $(C_1$-$C_4)$alkyl or Ar as defined above,

$C(R_{a_4})$=N-Rb wherein:

$R_{a_4}$ is H, Ar as defined above, or $(C_3$-$C_5)$cycloalkyl optionally substituted with $(C_1$-$C_4)$alkyl or Ar as defined above, and

Rb is $(C_1$-$C_2)$alkyl, $(C_3$-$C_5)$cycloalkyl, hydroxyl, $(C_1$-$C_4)$alkoxy, $(C_2$-$C_4)$alkenyloxy, or $(C_1$-$C_4)$alkylenoxy wherein said $(C_1$-$C_4)$alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, $(CH_2)_n$Ar wherein n is 0 or 1 and Ar is as defined above, $(C_1$-$C_4)$alkoxy, $NH_2$, $NH(C_1$-$C_4)$alkyl, and $N((C_1$-$C_4)alkyl)_2$ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,

$NH$-$C(O)R_{a_4}$ wherein $R_{a_4}$ is H, Ar as defined above, or $(C_3$-$C_5)$cycloalkyl optionally substituted with $(C_1$-$C_4)$alkyl or Ar as defined above,

$NHR_{a_4}$ wherein $R_{a_4}$ is H, Ar as defined above, or $(C_3$-$C_5)$cycloalkyl optionally substituted with $(C_1$-$C_4)$alkyl or Ar as defined above,

phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and

when Z is $SO_2R_3$ or $COR_3$, $R_2$ is carboxyl, $NH_2$, $NH(C_1$-$C_4)$alkyl, $N((C_1$-$C_4)alkyl)_2$ or $(C_3$-$C_5)$cycloalkylamino; or

a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or

a pharmacetically acceptable salt of the compound of formula (1) or formula (2).

2. The compound according to claim 1 wherein Ar is phenyl, 4-fluorophenyl or 4-methoxyphenyl.

3. The compound according to claim 2 wherein $R_1$ is H, $(C_1$-$C_4)$alkyl, phenyl or substituted phenyl.

4. The compound according to claim 3 wherein X and Y is each N and Z is H.

5. The compound according to claim 4 wherein $R_2$ is C(O)-$ORa_1$ and wherein $Ra_1$ is $(C_1$-$C_4)$alkyl.

6. The compound according to claim 5 selected from the group consisting of:

ethyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
isopropyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
methyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(+)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6,6-bis(4-methoxyphenyl)-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-(3,4-dimethoxyphenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl (-)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl (+)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,

ethyl 6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazole-3-carboxylate, and
ethyl 7-methyl-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxylate.

7. The compound according to claim 4 wherein $R_2$ is $CORa_4$ and $Ra_4$ is Ar or $(C_3\text{-}C_5)$cycloalkyl.

8. The compound according to claim 7 selected from the group consisting of:

cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)phenylmethanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)-(1H-pyrrol-3-yl)methanone,
6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(-)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(+)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone, and
cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone.

9. The compound according to claim 4 wherein $R_2$ is C(O)-$NHRa_2$, C(O)-$N(Ra_3)$-$ORa_3$ or C(O)-$N(Ra_2')$.

10. The compound according to claim 9 selected from the group consisting of:

N-(cyclopropyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide,
azetidin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(N-methoxy-N-methyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide, and
aziridin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone.

11. The compound according to claim 4 wherein $R_2$ is $C(Ra_4)$=N-Rb.

12. The compound according to claim 11 selected from the group consisting of:

(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl) methanone oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl) methanone oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl) methanone oxime,
(E,Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(E,Z)6,6-diphenyl-6,6-dihydro-1H-indazole-3-carbaldehyde O-methyloxime,
(E, Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,

(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-benzyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-benzyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-benzyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(4-nitrobenzyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(4-nitrobenzyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(4-nitrobenzyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-dimethylaminoethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-dimethylaminoethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-dimethylaminoethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-fluoroethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-fluoroethyl)oxime,

(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-fluoroethyl)oxime,
(E,Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(E)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(-)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(-)-6-(E)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(+)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(E,Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime, and
(E)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime.

13. The compound according to claim 4 wherein $R_2$ is NH-C(O)$Ra_4$.

14. The compound according to claim 13 selected from the group consisting of:

N-(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)cyclopropylamide, and
N-[6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl]benzamide

15. The compound according to claim 4 wherein $R_2$ is Ar.

16. The compound according to claim 15 selected from the group consisting of:

3-(3-methyl[1,2,4]oxadiazol-5-yl)-6,6-diphenyl-6,7-dihydro-1H-indazole,

3,6,6-triphenyl-6,7-dihydro-1H-indazole,
6,6-diphenyl-3-pyrid-3-yl-6,7-dihydro-1H-indazole, and
6,6-diphenyl-3-thiophen-3-yl-6,7-dihydro-1H-indazole.

17. The compound according to claim 4 wherein $R_2$ is CN.

18. The compound according to claim 14 wherein the compound is 6,6-diphenyl-6,7-dihydro-1H-indazole-3-carbonitrile.

19. The compound according to claim 1 wherein Z is $SO_2R_3$ or $COR_3$.

20. The compound according to claim 19 selected from the group consisting of:

6,6-diphenyl-1-(4-toluenesulphonyl)-6,7-dihydro-1H-indazol-3-ylamine and

1-(3-Amino-6,6-diphenyl-6,7-dihydroindazol-1-yl)propenone.

21. The compound according to claim 1 wherein Z is 4-aminophenyl.

22. The compound according to claim 21 wherein the compound is ethyl 1-(4-aminophenyl)-6,6-diphenyl-1H-indazole-3-carboxylate.

23. The compound according to claim 1 wherein X is CH, Y is N and $R_2$ is $C(O)\text{-}ORa_1$.

24. The compound according to claim 23 wherein the compound is ethyl 5,5-diphenyl-4,5-dihydro-2H-isoindole-1-carboxylate.

25. The compound according to claim 1 wherein X is N, Y is CH and $R_2$ is $C(O)\text{-}ORa_1$.

26. The compound according to claim 25 wherein the compound is ethyl 6,6-diphenyl-6,7-dihydro-1H-indole-3-carboxylate.

27. A method for the treatment of tumors comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (1) or formula (2)



(1)



(2)

wherein:

X and Y independently are N or CH wherein at least one of X and Y is N;

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, thio$(C_1\text{-}C_4)$alkyl, $NO_2$, NH$(C_1\text{-}C_4)$alkyl and N$((C_1\text{-}C_4)\text{alkyl})_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, or

5 or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, thio$(C_1\text{-}C_4)$alkyl, NH$(C_1\text{-}C_4)$alkyl, N$((C_1\text{-}C_4)\text{alkyl})_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N,

Z is H, 4-aminophenyl, $SO_2R_3$ or $COR_3$ wherein $R_3$ is $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, Ar as defined above, $(C_2\text{-}C_6)$alkenyl or $(C_2\text{-}C_6)$alkynyl;

$R_1$ is H, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl or Ar as defined above;

R' is H or $(C_1\text{-}C_4)$alkyl; and

when Z is H, $R_2$ is a selected from the group consisting of:

cyano,

C(O)-O$Ra_1$ wherein $Ra_1$ is methyl, ethyl or isopropyl,

C(O)-NH$Ra_2$ wherein $Ra_2$ is cyclopropyl,

C(O)-N($Ra_2$'), wherein N($Ra_2$') is aziridinyl or azetidinyl, optionally substituted with ($C_1$-$C_4$)alkyl or Ar as defined above,

C(O)-N($Ra_3$)-O$Ra_3$ wherein each $Ra_3$ may be identical or different and each $Ra_3$ is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

C(O)$Ra_4$ wherein $Ra_4$ is Ar as defined above or ($C_3$-$C_5$)cycloalkyl optionally substituted with ($C_1$-$C_4$)alkyl or Ar as defined above,

C($Ra_4$)=N-Rb wherein:

$Ra_4$ is H, Ar as defined above, or ($C_3$-$C_5$)cycloalkyl optionally substituted with ($C_1$-$C_4$)alkyl or Ar as defined above, and

Rb is ($C_1$-$C_2$)alkyl, ($C_3$-$C_5$)cycloalkyl, hydroxyl, ($C_1$-$C_4$)alkoxy, ($C_2$-$C_4$)alkenyloxy, or ($C_1$-$C_4$)alkylenoxy wherein said ($C_1$-$C_4$)alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, ($CH_2$)$_n$Ar wherein n is 0 or 1 and Ar is as defined above, ($C_1$-$C_4$)alkoxy, $NH_2$, NH($C_1$-$C_4$)alkyl, and N(($C_1$-$C_4$)alkyl)$_2$ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,

NH-C(O)$Ra_4$ wherein $Ra_4$ is H, Ar as defined above, or ($C_3$-$C_5$)cycloalkyl optionally substituted with ($C_1$-$C_4$)alkyl or Ar as defined above,

NH$Ra_4$ wherein $Ra_4$ is H, Ar as defined above, or ($C_3$-$C_5$)cycloalkyl optionally substituted with ($C_1$-$C_4$)alkyl or Ar as defined above,

phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and

when Z is $SO_2R_3$ or $COR_3$, $R_2$ is carboxyl, $NH_2$, NH($C_1$-$C_4$)alkyl, N(($C_1$-$C_4$)alkyl)$_2$ or ($C_3$-$C_5$)cycloalkylamino; or

a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or
a pharmacetically acceptable salt of the compound of formula (1) or formula (2).

28. The method of claim 27 wherein the therapeutically effective amount comprises an amount sufficient to inhibit microtubule polymerization.

29. The method of claim 27 wherein the therapeutically effective amount comprises a therapeutically effective endothelial cell detaching amount.

30. The method of claim 27 wherein the therapeutically effective amount comprises an amount sufficient to inhibit vascularization of said tumors.

31. A method for the treatment of cancerous cells comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (1) or formula (2)




(1)




(2)

wherein:
X and Y independently are N or CH wherein at least one of X and Y is N;
Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, thio$(C_1\text{-}C_4)$alkyl, $NO_2$, NH$(C_1\text{-}C_4)$alkyl and N$((C_1\text{-}C_4)\text{alkyl})_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N, or

5 or 6 membered aromatic heterocycle containing one or two hetero atoms selected from the group consisting of O, N and S, and optionally substituted with one or more halogen, $(C_1-C_4)$alkyl, $(C_1-C_4)$alkoxy, thio$(C_1-C_4)$alkyl, NH$(C_1-C_4)$alkyl, N$((C_1-C_4)alkyl)_2$ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of said heterocycle wherein said 4 to 6 membered ring may optionally contain a second hetero atom selected from the group consisting of O, S and N,

Z is H, 4-aminophenyl, $SO_2R_3$ or $COR_3$ wherein $R_3$ is $(C_1-C_4)$alkyl, $(C_3-C_6)$cycloalkyl, Ar as defined above, $(C_2-C_6)$alkenyl or $(C_2-C_6)$alkynyl;

$R_1$ is H, $(C_1-C_4)$alkyl, $(C_3-C_6)$cycloalkyl or Ar as defined above;

R' is H or $(C_1-C_4)$alkyl; and

when Z is H, $R_2$ is a selected from the group consisting of:

cyano,

C(O)-O$Ra_1$ wherein $Ra_1$ is methyl, ethyl or isopropyl,

C(O)-NH$Ra_2$ wherein $Ra_2$ is cyclopropyl,

C(O)-N($Ra_2$'), wherein N($Ra_2$') is aziridinyl or azetidinyl, optionally substituted with $(C_1-C_4)$alkyl or Ar as defined above,

C(O)-N($Ra_3$)-O$Ra_3$ wherein each $Ra_3$ may be identical or different and each $Ra_3$ is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

C(O)$Ra_4$ wherein $Ra_4$ is Ar as defined above or $(C_3-C_5)$cycloalkyl optionally substituted with $(C_1-C_4)$alkyl or Ar as defined above,

C($Ra_4$)=N-Rb wherein:

$Ra_4$ is H, Ar as defined above, or $(C_3-C_5)$cycloalkyl optionally substituted with $(C_1-C_4)$alkyl or Ar as defined above, and

Rb is $(C_1-C_2)$alkyl, $(C_3-C_5)$cycloalkyl, hydroxyl, $(C_1-C_4)$alkoxy, $(C_2-C_4)$alkenyloxy, or $(C_1-C_4)$alkylenoxy wherein said $(C_1-C_4)$alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, $(CH_2)_n$Ar wherein n is 0 or 1 and Ar is as defined above, $(C_1-C_4)$alkoxy, $NH_2$, NH$(C_1-C_4)$alkyl, and N$((C_1-C_4)alkyl)_2$ wherein said alkyls together with the heteroatom to which they are attached may optionally form

a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,

$NH\text{-}C(O)Ra_4$ wherein $Ra_4$ is H, Ar as defined above, or $(C_3\text{-}C_5)$cycloalkyl optionally substituted with $(C_1\text{-}C_4)$alkyl or Ar as defined above,

$NHRa_4$ wherein $Ra_4$ is H, Ar as defined above, or $(C_3\text{-}C_5)$cycloalkyl optionally substituted with $(C_1\text{-}C_4)$alkyl or Ar as defined above,

phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and

when Z is $SO_2R_3$ or $COR_3$, $R_2$ is carboxyl, $NH_2$, $NH(C_1\text{-}C_4)$alkyl, $N((C_1\text{-}C_4)alkyl)_2$ or $(C_3\text{-}C_5)$cycloalkylamino; or

a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or

a pharmacetically acceptable salt of the compound of formula (1) or formula (2).

32. The method of claim 31 wherein the therapeutically effective amount comprises an amount sufficient to inhibit microtubule polymerization.

33. The method of claim 31 wherein the therapeutically effective amount comprises a therapeutically effective endothelial cell detaching amount.

34. The method of claim 31 wherein the therapeutically effective amount comprises an amount sufficient to inhibit vascularization of said cancerous cells.

35. A pharmaceutical composition comprising one or more compounds of formula (1) or formula (2) according to claim 1 and one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.